Oppenheimer Upgrades Cypress Bioscience (CYPB) to Outperform
More News related to CYPB
- Cypress Bioscience, Inc. to Participate in BIO CEO & Investor Conference
- A Fibromyalgia Drug That Improves Sleep Quality More Than Pfizer's Lyrica Would Earn Sizeable Patient Share in the U.S. and Europe
- Roth Capital Initiates Coverage on Cypress Bioscience (CYPB) with a Buy
- Oppenheimer Upgrades Cypress Bioscience (CYPB) to Outperform
- Forest Lab (FRX) and Cypress Bio (CYPB) Announce Savella Phase III Results
More News related to Upgrades
- Soleil Securities Upgrades Zebra Technologies (ZBRA) to Gradually Accumulate; Valuation Call
- UBS Issues Intraday Upgrade on Cimarex Energy (XEC)
- Boenning & Scattergood Upgrades Equinix (EQIX) to Outperform
- Avondale Partners Upgrades ADC Telecommunications (ADCT) to Market Outperform
- Johnson Rice Upgrades Pool Corp (POOL) to Overweight
Oppenheimer upgrades Cypress Bioscience (Nasdaq: CYPB) from Perform to Outperform. Price target $9.
To see more analyst ratings on CYPB Click Here.
Cypress Bioscience, Inc. provides therapeutics and personalized medicine services.
Related Categories
UpgradesStocks Mentioned
+0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
